Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- PMID: 25301630
- PMCID: PMC4636050
- DOI: 10.1126/science.1253462
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Abstract
Spatial and temporal dissection of the genomic changes occurring during the evolution of human non-small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We sequenced 25 spatially distinct regions from seven operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome-doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. The regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC.
Copyright © 2014, American Association for the Advancement of Science.
Figures
Comment in
-
Cancer. Attack of the clones.Science. 2014 Oct 10;346(6206):169-70. doi: 10.1126/science.1259926. Science. 2014. PMID: 25301605 No abstract available.
-
Lung cancer: Heterogeneity in space and time.Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.186. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348786 No abstract available.
-
Tumour evolution: clonal ancestry in lung cancer.Nat Rev Cancer. 2014 Dec;14(12):763. doi: 10.1038/nrc3867. Nat Rev Cancer. 2014. PMID: 25568921 No abstract available.
Similar articles
-
Tracking the Evolution of Non-Small-Cell Lung Cancer.N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26. N Engl J Med. 2017. PMID: 28445112
-
Lung cancer: Heterogeneity in space and time.Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.186. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348786 No abstract available.
-
Cancer. Attack of the clones.Science. 2014 Oct 10;346(6206):169-70. doi: 10.1126/science.1259926. Science. 2014. PMID: 25301605 No abstract available.
-
Generation of Genomic Alteration from Cytidine Deamination.Adv Exp Med Biol. 2018;1044:49-64. doi: 10.1007/978-981-13-0593-1_5. Adv Exp Med Biol. 2018. PMID: 29956291 Review.
-
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Cancer Discov. 2015 Jul;5(7):704-12. doi: 10.1158/2159-8290.CD-15-0344. Epub 2015 Jun 19. Cancer Discov. 2015. PMID: 26091828 Free PMC article. Review.
Cited by
-
Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.Cancer Discov. 2015 Aug;5(8):821-831. doi: 10.1158/2159-8290.CD-15-0412. Epub 2015 May 23. Cancer Discov. 2015. PMID: 26003801 Free PMC article.
-
Deciphering intratumor heterogeneity using cancer genome analysis.Hum Genet. 2016 Jun;135(6):635-42. doi: 10.1007/s00439-016-1670-x. Epub 2016 Apr 28. Hum Genet. 2016. PMID: 27126234 Review.
-
Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging.Clin Radiol. 2017 Jan;72(1):3-10. doi: 10.1016/j.crad.2016.09.013. Epub 2016 Oct 11. Clin Radiol. 2017. PMID: 27742105 Free PMC article. Review.
-
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.Nat Commun. 2016 Apr 5;7:11111. doi: 10.1038/ncomms11111. Nat Commun. 2016. PMID: 27045317 Free PMC article.
-
Understanding EGFR heterogeneity in lung cancer.ESMO Open. 2020 Oct;5(5):e000919. doi: 10.1136/esmoopen-2020-000919. ESMO Open. 2020. PMID: 33067323 Free PMC article. Review.
References
-
- World Health Organization 2013 www.who.int/cancer/en/
-
- Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin. 2013;63:11–30. - PubMed
-
- Tanaka H, et al. Cancer Res. 2007;67:6007–6011. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- A4688/CRUK_/Cancer Research UK/United Kingdom
- 091730/WT_/Wellcome Trust/United Kingdom
- 18377/CRUK_/Cancer Research UK/United Kingdom
- 105104/WT_/Wellcome Trust/United Kingdom
- 088340/WT_/Wellcome Trust/United Kingdom
- 17001/CRUK_/Cancer Research UK/United Kingdom
- A19310/CRUK_/Cancer Research UK/United Kingdom
- G0902275/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- 17786/CRUK_/Cancer Research UK/United Kingdom
- A11590/CRUK_/Cancer Research UK/United Kingdom
- A17786/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical